Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Receivables (2023 - 2025)

Krystal Biotech's Receivables history spans 3 years, with the latest figure at $127.4 million for Q4 2025.

  • For Q4 2025, Receivables rose 21.63% year-over-year to $127.4 million; the TTM value through Dec 2025 reached $127.4 million, up 21.63%, while the annual FY2025 figure was $127.4 million, 21.63% up from the prior year.
  • Receivables for Q4 2025 was $127.4 million at Krystal Biotech, down from $129.6 million in the prior quarter.
  • Across five years, Receivables topped out at $129.6 million in Q3 2025 and bottomed at $9.3 million in Q3 2023.
  • The 3-year median for Receivables is $104.0 million (2024), against an average of $93.3 million.
  • The largest annual shift saw Receivables skyrocketed 946.22% in 2024 before it dropped 1.38% in 2025.
  • A 3-year view of Receivables shows it stood at $42.0 million in 2023, then surged by 149.16% to $104.7 million in 2024, then increased by 21.63% to $127.4 million in 2025.
  • Per Business Quant, the three most recent readings for KRYS's Receivables are $127.4 million (Q4 2025), $129.6 million (Q3 2025), and $111.4 million (Q2 2025).